This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—There are relatively few reports as yet in the American literature on the efficacy of clozapine. I am reporting on a three-year case history follow-up of 37 schizophrenic patients (out of an initial cohort of 50) who had participated in a doubleblind, hospital-based drug trial of clozapine vs chlorpromazine for a sixweek period.1 Clozapine (chloro-methylpiperazinyl-dibenzo-diazepine) is of interest because it is a derivative of the diabenzapines (related to the tricyclic compounds) that has been found to have antipsychotic properties, although pharmacologically it does not behave like a neuroleptic.2 It has been shown to be practically free of extrapyramidal effects since it is essentially an anticholinergic.3,4
The initial report requires expansion since it did not emphasize sufficiently the fact that the clozapine capsules mistakenly contained a dose double that which was initially planned. Hence, the mean daily dosage for both drugs fluctuated around 600 mg.
LEON CA. Efficacy of Clozapine. Arch Gen Psychiatry. 1978;35(7):905. doi:10.1001/archpsyc.1978.01770310111012
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.